A chimeric tri-functional peptide combining cell penetration, nuclear targeting, and a cancer pathway-blocking sequence induced tumor cell death and shrank breast cancer tumors in mice by disrupting the TEAD-YAP interaction in the Hippo signaling pathway.
Tri-functional designOne chimeric peptide combines cell penetration, nuclear localization, and therapeutic protein-protein interaction disruption — solving the delivery challenge and delivering the cancer-killing payload in a single molecule
What the researchers found
The chimeric tri-functional peptide combined three functional domains into one molecule:
1. A cell-penetrating peptide (CPP) for cellular uptake
2. A nuclear localization sequence (NLS) for targeting to the nucleus
3. An interfering peptide that blocks the TEAD-YAP protein-protein interaction
Results demonstrated:
• Successful cell penetration and nuclear localization confirmed by flow cytometry and fluorescence microscopy
• Apoptotic (cell death) effects in tumor cell lines
• Anti-tumoral effects in vivo in breast cancer xenograft mouse models
• The specific nuclear delivery of the interfering cargo was essential for the anti-cancer effect
Why it matters
The TEAD-YAP interaction has been a 'hot target' in cancer research but extremely difficult to drug because it occurs inside the nucleus. Traditional drugs struggle to cross cell membranes, let alone reach the nucleus. This tri-functional peptide solves both delivery challenges in a single molecule while also carrying the therapeutic payload, demonstrating a generalizable design principle for targeting nuclear protein-protein interactions in cancer.
How the study worked
The peptide was designed as a chimeric construct with three functional domains. Cell penetration and nuclear localization were validated using flow cytometry and fluorescence microscopy. Anti-cancer activity was tested in vitro on tumor cell lines (measuring apoptosis) and in vivo using xenograft models of breast cancer in mice.
What this study cannot tell us
Preclinical study with no human data. Xenograft mouse models use human tumors in immunodeficient mice, which don't fully replicate the human tumor microenvironment. Peptide stability and pharmacokinetics in vivo are not discussed in the abstract. The specific tumor cell lines used and quantitative efficacy data are not detailed. Manufacturing complexity of multi-domain chimeric peptides could limit clinical translation. Potential immunogenicity of the CPP domain was not addressed.
How to read the evidence
This is a preclinical proof-of-concept study demonstrating a novel peptide design principle in cell lines and mouse xenograft models. While the results are encouraging, the study represents early-stage drug development. No human data or comparative studies exist for this approach.
When this study was published
Published in 2019, this study introduced a creative peptide engineering approach. Since then, small-molecule inhibitors of TEAD-YAP have advanced further in clinical development, but the tri-functional peptide design principle remains relevant for other nuclear targets.
The bigger picture
Protein-protein interactions in the nucleus have been called 'undruggable' because of the multiple barriers between a drug and its target. This chimeric peptide approach overcomes this by engineering delivery into the molecule itself. The Hippo pathway is just one example — the same tri-functional design principle could potentially be applied to any nuclear protein-protein interaction in cancer, making this a platform technology rather than a single drug candidate.
Questions still open
- Can this tri-functional peptide design be adapted to target other nuclear protein-protein interactions beyond TEAD-YAP?
- What is the peptide's stability and half-life in vivo, and can it be improved for clinical use?
- How does this peptide approach compare to small-molecule TEAD-YAP inhibitors now in clinical development?
Common questions
What is a chimeric peptide?
Why is the Hippo pathway important in cancer?
Read the original research
New Therapeutic Approach for Targeting Hippo Signalling Pathway.
Scientific reports, 9(1), 4771
Citation
Dominguez-Berrocal, Leticia; Cirri, Erica; Zhang, Xiguang; Andrini, Laura; Marin, Gustavo H; Lebel-Binay, Sophie; Rebollo, Angelita. (2019). New Therapeutic Approach for Targeting Hippo Signalling Pathway.. Scientific reports, 9(1), 4771. https://doi.org/10.1038/s41598-019-41404-w